81 related articles for article (PubMed ID: 11594684)
1. Targets of anti-influenza chemotherapy other than neuraminidase and proton pump.
Shigeta S
Antivir Chem Chemother; 2001; 12 Suppl 1():179-88. PubMed ID: 11594684
[TBL] [Abstract][Full Text] [Related]
2. [Current status of research and development for anti-influenza virus drugs--chemotherapy for influenza].
Shigeta S
Nihon Rinsho; 1997 Oct; 55(10):2758-64. PubMed ID: 9360403
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in anti-influenza chemotherapy.
Shigeta S
Drugs R D; 1999 Sep; 2(3):153-64. PubMed ID: 10641217
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
Liu AL; Wang HD; Lee SM; Wang YT; Du GH
Bioorg Med Chem; 2008 Aug; 16(15):7141-7. PubMed ID: 18640042
[TBL] [Abstract][Full Text] [Related]
5. Anti-infective therapy for viral pneumonia.
Mahmood W; Sacks SL
Semin Respir Infect; 1995 Dec; 10(4):270-81. PubMed ID: 8668855
[TBL] [Abstract][Full Text] [Related]
6. Respiratory viruses predisposing to bacterial infections: role of neuraminidase.
Peltola VT; McCullers JA
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S87-97. PubMed ID: 14730275
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo.
Shigeta S; Mori S; Watanabe J; Soeda S; Takahashi K; Yamase T
Antimicrob Agents Chemother; 1997 Jul; 41(7):1423-7. PubMed ID: 9210659
[TBL] [Abstract][Full Text] [Related]
8. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
[TBL] [Abstract][Full Text] [Related]
9. Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues.
Ho HT; Hurt AC; Mosse J; Barr I
Antiviral Res; 2007 Dec; 76(3):263-6. PubMed ID: 17868928
[TBL] [Abstract][Full Text] [Related]
10. Anti-influenza virus activity of biflavonoids.
Miki K; Nagai T; Suzuki K; Tsujimura R; Koyama K; Kinoshita K; Furuhata K; Yamada H; Takahashi K
Bioorg Med Chem Lett; 2007 Feb; 17(3):772-5. PubMed ID: 17110111
[TBL] [Abstract][Full Text] [Related]
11. A monoclonal antibody specific to the HA2 glycoprotein of influenza A virus hemagglutinin that inhibits its fusion activity reduces replication of the virus.
Varecková E; Wharton SA; Mucha V; Gocník M; Kostolanský F
Acta Virol; 2003; 47(4):229-36. PubMed ID: 15068378
[TBL] [Abstract][Full Text] [Related]
12. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.
Lackenby A; Democratis J; Siqueira MM; Zambon MC
Antivir Ther; 2008; 13(6):809-20. PubMed ID: 18839782
[TBL] [Abstract][Full Text] [Related]
13. Anti-RNA virus activity of polyoxometalates.
Shigeta S; Mori S; Yamase T; Yamamoto N; Yamamoto N
Biomed Pharmacother; 2006 Jun; 60(5):211-9. PubMed ID: 16737794
[TBL] [Abstract][Full Text] [Related]
14. The role of target membrane sialic acid residues in the fusion activity of the influenza virus: the effect of two types of ganglioside on the kinetics of membrane merging.
Ramalho-Santos J; Pedroso De Lima MC
Cell Mol Biol Lett; 2004; 9(2):337-51. PubMed ID: 15213813
[TBL] [Abstract][Full Text] [Related]
15. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
Wen WH; Lin M; Su CY; Wang SY; Cheng YS; Fang JM; Wong CH
J Med Chem; 2009 Aug; 52(15):4903-10. PubMed ID: 19522501
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo influenza virus-inhibitory effects of viramidine.
Sidwell RW; Bailey KW; Wong MH; Barnard DL; Smee DF
Antiviral Res; 2005 Oct; 68(1):10-7. PubMed ID: 16087250
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.
Ilyushina NA; Bovin NV; Webster RG; Govorkova EA
Antiviral Res; 2006 Jul; 70(3):121-31. PubMed ID: 16516984
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season.
Saito R; Li D; Suzuki Y; Sato I; Masaki H; Nishimura H; Kawashima T; Shirahige Y; Shimomura C; Asoh N; Degawa S; Ishikawa H; Sato M; Shobugawa Y; Suzuki H
J Med Virol; 2007 Oct; 79(10):1569-76. PubMed ID: 17705168
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Gubareva LV
Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
